Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Athersys (ATHX) Share Price

Share on StockTwits

Media coverage about Athersys (NASDAQ:ATHX) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Athersys earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 48.4981047687524 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have impacted Accern’s rankings:

ATHX traded down $0.04 during midday trading on Wednesday, hitting $2.02. The stock had a trading volume of 438,607 shares, compared to its average volume of 694,877. The firm has a market cap of $285.48 million, a P/E ratio of -6.97 and a beta of -0.65. Athersys has a 1 year low of $1.29 and a 1 year high of $3.09.

Athersys (NASDAQ:ATHX) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $19.39 million during the quarter, compared to analyst estimates of $12.82 million. Athersys had a negative return on equity of 61.52% and a negative net margin of 106.99%. equities research analysts anticipate that Athersys will post -0.21 EPS for the current year.

Several brokerages have issued reports on ATHX. BidaskClub lowered Athersys from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. Zacks Investment Research lowered Athersys from a “buy” rating to a “sell” rating in a research note on Wednesday, July 11th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $6.00 target price on shares of Athersys in a research note on Wednesday, August 8th.

In other news, EVP John J. Harrington sold 15,000 shares of the stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $2.30, for a total transaction of $34,500.00. Following the completion of the sale, the executive vice president now owns 612,503 shares of the company’s stock, valued at $1,408,756.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider William Lehmann, Jr. sold 30,000 shares of the stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $2.25, for a total value of $67,500.00. Following the sale, the insider now directly owns 460,084 shares of the company’s stock, valued at approximately $1,035,189. The disclosure for this sale can be found here. In the last ninety days, insiders sold 91,088 shares of company stock valued at $194,637. 18.60% of the stock is owned by insiders.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Featured Story: Dividend

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply